Carcinoid syndrome and serotonin: therapeutic effects of ketanserin
- PMID: 2285651
- DOI: 10.1007/BF00053427
Carcinoid syndrome and serotonin: therapeutic effects of ketanserin
Abstract
The carcinoid syndrome can arise when effluent blood from carcinoid tumor tissue gains access to the systemic, as opposed to the portal, venous system. Features include facial flushing, diarrhea, wheezing, right-sided cardiac lesions, and retroperitoneal fibrosis. Attacks of flushing, diarrhea, and wheezing can be provoked by bolus injections of adrenaline, noradrenaline, or pentagastrin. While serotonin usually predominates, carcinoid tumors can also secrete, in varying proportions, 5-hydroxytryptophan, kallikrein, kinins, substance P and other neuropeptides, prostaglandins, catecholamines, and histamine. Of these, serotonin, kinins, histamine, and substance P are possible mediators of flushes; serotonin and substance P of hyperperistalsis; and serotonin, kinins, or histamine of bronchial constriction. Despite the gross excess of circulating serotonin, nearly all is platelet bound and therefore inactive. Very little is free in plasma. Demonstration of a contribution of serotonin to carcinoid attacks requires assay of free plasma serotonin; measurements of whole blood or serum serotonin are of little value. Some, but not all, provoked flushes have been shown to be accompanied by a rise in free plasma serotonin or substance P; an increase in circulating kinins has been more consistently shown. The 5HT2 antagonist ketanserin has been found to inhibit both provoked and spontaneous attacks of flushing, diarrhea, and dyspnea in a proportion of patients with carcinoid syndrome.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
The pentagastrin test in the diagnosis of the carcinoid syndrome. Blockade of gastrointestinal symptoms by ketanserin.Ann Surg. 1985 Jan;201(1):81-6. Ann Surg. 1985. PMID: 2578277 Free PMC article.
-
[Symptomatic relief of carcinoid syndrome by ketanserin. A case].Presse Med. 1995 May 27;24(19):897-9. Presse Med. 1995. PMID: 7638130 French.
-
Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.Am J Gastroenterol. 1997 Dec;92(12):2250-6. Am J Gastroenterol. 1997. PMID: 9399764 Clinical Trial.
-
Carcinoid heart disease: a clinical pathologic, and therapeutic update.Curr Probl Cardiol. 1982 Feb;6(11):1-42. doi: 10.1016/0146-2806(82)90013-5. Curr Probl Cardiol. 1982. PMID: 7044696 Review.
-
Pharmacology of the carcinoid syndrome.Lancet. 1968 Feb 24;1(7539):404-5. Lancet. 1968. PMID: 4169981 Review. No abstract available.
Cited by
-
Carcinoid Heart Disease.Curr Treat Options Cardiovasc Med. 2000 Oct;2(5):399-406. doi: 10.1007/s11936-000-0035-9. Curr Treat Options Cardiovasc Med. 2000. PMID: 11096544
-
Pathogenesis and Clinical Management of Mesenteric Fibrosis in Small Intestinal Neuroendocine Neoplasms: A Systematic Review.J Clin Med. 2020 Jun 8;9(6):1777. doi: 10.3390/jcm9061777. J Clin Med. 2020. PMID: 32521677 Free PMC article. Review.
-
Fibrosis and carcinoid syndrome: from causation to future therapy.Nat Rev Endocrinol. 2009 May;5(5):276-83. doi: 10.1038/nrendo.2009.51. Nat Rev Endocrinol. 2009. PMID: 19444261 Review.
-
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.Neoplasia. 2017 Dec;19(12):991-1002. doi: 10.1016/j.neo.2017.09.002. Epub 2017 Nov 5. Neoplasia. 2017. PMID: 29091800 Free PMC article. Review.
-
Serotonin and vascular disease: a survey.Cardiovasc Drugs Ther. 1990 Jan;4 Suppl 1:137-40. doi: 10.1007/BF00053446. Cardiovasc Drugs Ther. 1990. PMID: 2285645 Review. No abstract available.